Based on these neuroinflammatory hypotheses, we have quantified the numerical density of immunostained CD3+ T-lymphocytes, CD20+ B-lymphocytes, and HLA-DR+ microglial cells in the posterior hippocampus of 17 schizophrenia patients and 11 matched controls. Disease course-related immune alterations were considered by a separate analysis of residual (prevailing negative symptoms, n = 7) and paranoid (prominent positive symptoms, n = 10) schizophrenia cases.
Higher densities of CD3+ and CD20+ lymphocytes were observed in residual versus paranoid schizophrenia (CD 3: left: P = 0.047, right: P = 0.038; CD20: left: P = 0.020, right: P = 0.010) and controls (CD3: left: P = 0.057, right: P = 0.069; CD20: left: P = 0.008, right: P = 0.006). In contrast, HLA-DR+ microglia were increased in paranoid schizophrenia versus residual schizophrenia (left: P = 0.030, right: P = 0.012). A similar trend emerged when this group was compared to controls (left: P = 0.090, right: P = 0.090).
BBB impairment and infiltration of T cells and B cells may contribute to the pathophysiology of residual schizophrenia, while microglial activation seems to play a role in paranoid schizophrenia. The identification of diverse immune endophenotypes may facilitate the development of distinct anti-inflammatory schizophrenia therapies to normalize BBB function, (auto)antibody production or microglial activity.